Docetaxel, cisplatin and capecitabine (DCX) as perioperative chemotherapy in gastro-esophageal adenocarcinoma. (Mature results of a phase II study of the Arbeitsgemeinschaft Internistische Onkologie AIO)

4116 Background: Perioperative chemotherapy with ECF or ECX is the standard approach in Europe for resectable gastroesophageal cancer. Docetaxel significantly improves efficacy if added to cisplatin and 5-FU as palliative treatment. To translate this efficacy into the curative approach this study investigates docetaxel (D), cisplatin (C) and capecitabine (X) in the perioperative setting. Methods: Pts with curatively resectable adenocarcinoma of the distal esophagus, gastroesophageal junction (GEJ) or stomach were treated with 3 preop and 3 postop cycles of chemotherapy: D 75 mg/m2 d1, C 60 mg/m2 d1 and × 1875 mg/m2/d d1-14, q3w. G-CSF was not routinely administered. Results: Accrual is completed with 50 pts included. Here we report on the protocol specified interim safety analysis of the preop chemo and surgery after 15 patients: male/female:15/0; med. age 65 yrs (45-73); esophagus/GEJ/stomach: 2/12/1 pts; ECOG PS 0/1/2: 7/8/0 pts; reduction of preop chemo was necessary in 7/15 pts; chemo toxicity, see Ta...